MX2012009817A - Sintesis de magnolol y sus compuestos analogos. - Google Patents
Sintesis de magnolol y sus compuestos analogos.Info
- Publication number
- MX2012009817A MX2012009817A MX2012009817A MX2012009817A MX2012009817A MX 2012009817 A MX2012009817 A MX 2012009817A MX 2012009817 A MX2012009817 A MX 2012009817A MX 2012009817 A MX2012009817 A MX 2012009817A MX 2012009817 A MX2012009817 A MX 2012009817A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- formula
- magnolol
- bisphenol
- organic solvent
- Prior art date
Links
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 title claims abstract description 133
- 150000001875 compounds Chemical class 0.000 title claims description 42
- 238000003786 synthesis reaction Methods 0.000 title description 13
- 230000015572 biosynthetic process Effects 0.000 title description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 106
- 238000000034 method Methods 0.000 claims abstract description 31
- 238000004519 manufacturing process Methods 0.000 claims abstract description 25
- 238000006243 chemical reaction Methods 0.000 claims abstract description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 27
- 239000003960 organic solvent Substances 0.000 claims description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 20
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 claims description 18
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 16
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 claims description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 14
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 13
- 239000011777 magnesium Substances 0.000 claims description 13
- 229910052749 magnesium Inorganic materials 0.000 claims description 13
- IMHDGJOMLMDPJN-UHFFFAOYSA-N biphenyl-2,2'-diol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1O IMHDGJOMLMDPJN-UHFFFAOYSA-N 0.000 claims description 11
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 claims description 9
- 150000007530 organic bases Chemical class 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 230000008878 coupling Effects 0.000 claims description 6
- 238000010168 coupling process Methods 0.000 claims description 6
- 238000005859 coupling reaction Methods 0.000 claims description 6
- 239000012351 deprotecting agent Substances 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 239000000203 mixture Substances 0.000 description 12
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- -1 MOM ether compound Chemical class 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 5
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- DXECKNPVBYJOCG-GGWOSOGESA-N 4-[(e)-but-2-enyl]-2-[5-[(e)-but-2-enyl]-2-hydroxyphenyl]phenol Chemical compound C\C=C\CC1=CC=C(O)C(C=2C(=CC=C(C\C=C\C)C=2)O)=C1 DXECKNPVBYJOCG-GGWOSOGESA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000218378 Magnolia Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000004051 hexyl group Chemical class [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 125000001147 pentyl group Chemical class C(CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- AALUTIYNYXEFNT-UHFFFAOYSA-N trimethylsilane hydroiodide Chemical compound C[SiH](C)C.I AALUTIYNYXEFNT-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/48—Preparation of compounds having groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/01—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
- C07C37/055—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/62—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by introduction of halogen; by substitution of halogen atoms by other halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/48—Preparation of compounds having groups
- C07C41/50—Preparation of compounds having groups by reactions producing groups
- C07C41/52—Preparation of compounds having groups by reactions producing groups by substitution of halogen only
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2010/025378 WO2011106003A1 (en) | 2010-02-25 | 2010-02-25 | Synthesis of magnolol and its analogue compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012009817A true MX2012009817A (es) | 2012-09-12 |
Family
ID=42028117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012009817A MX2012009817A (es) | 2010-02-25 | 2010-02-25 | Sintesis de magnolol y sus compuestos analogos. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8519197B2 (enExample) |
| EP (1) | EP2539310B1 (enExample) |
| JP (1) | JP2013520495A (enExample) |
| CN (1) | CN102884035B (enExample) |
| AR (1) | AR080656A1 (enExample) |
| AU (1) | AU2010346597B2 (enExample) |
| BR (1) | BR112012020603A2 (enExample) |
| CA (1) | CA2789140C (enExample) |
| DK (1) | DK2539310T3 (enExample) |
| ES (1) | ES2507615T3 (enExample) |
| MX (1) | MX2012009817A (enExample) |
| MY (1) | MY162466A (enExample) |
| PH (1) | PH12012501619A1 (enExample) |
| PL (1) | PL2539310T3 (enExample) |
| RU (1) | RU2510938C1 (enExample) |
| SG (1) | SG183120A1 (enExample) |
| TW (1) | TWI438185B (enExample) |
| WO (1) | WO2011106003A1 (enExample) |
| ZA (1) | ZA201206020B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012087289A1 (en) | 2010-12-21 | 2012-06-28 | Colgate-Palmolive Company | Halogenated biphenols as antibacterial agents |
| BR112014014609B1 (pt) | 2011-12-15 | 2018-06-05 | Colgate-Palmolive Company | Composição compreendendo análogos de magnolol solubilizados. |
| CN104023698B (zh) | 2011-12-15 | 2016-10-05 | 高露洁-棕榄公司 | 溶解的厚朴酚类似物 |
| EP2794535B1 (en) | 2011-12-20 | 2016-04-20 | Colgate-Palmolive Company | Processes for making magnolol analogs |
| US9000231B2 (en) | 2011-12-20 | 2015-04-07 | Colgate-Palmolive Company | Processes for making magnolol and derivatives thereof |
| EP2948220B1 (en) | 2013-01-23 | 2018-07-04 | Colgate-Palmolive Company | Processes for making magnolol derivatives |
| JP2015007054A (ja) * | 2014-07-24 | 2015-01-15 | コルゲート・パーモリブ・カンパニーＣｏｌｇａｔｅ−Ｐａｌｍｏｌｉｖｅ Ｃｏｍｐａｎｙ | マグノロールおよびその類似体化合物の合成 |
| AU2016340992B2 (en) * | 2015-10-23 | 2020-10-08 | Colgate-Palmolive Company | Improved synthesis of honokiol |
| CN109053387B (zh) * | 2018-09-19 | 2021-07-09 | 九江学院 | 一种厚朴酚的合成方法 |
| US12311044B2 (en) | 2018-12-18 | 2025-05-27 | Conopco, Inc. | Antimicrobial composition |
| CN115581690A (zh) * | 2021-07-05 | 2023-01-10 | 北京红惠新医药科技有限公司 | 厚朴酚或和厚朴酚的芳环氨基取代衍生物在用于制备抗心肌缺血药物中的应用、药物组合物 |
| CN116139115A (zh) * | 2021-11-19 | 2023-05-23 | 北京红惠新医药科技有限公司 | 厚朴酚和/或和厚朴酚芳环氨基取代类衍生物的抗低氧/缺氧损伤用途及药物组合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA929051B (en) * | 1991-11-25 | 1994-05-23 | Lilly Co Eli | Substituted phenyl phenol leukotriene antagonists |
| US6544409B2 (en) | 2001-05-16 | 2003-04-08 | Petroleo Brasileiro S.A. - Petrobras | Process for the catalytic oxidation of sulfur, nitrogen and unsaturated compounds from hydrocarbon streams |
| CN1147286C (zh) * | 2001-07-18 | 2004-04-28 | 广州美晨股份有限公司 | 一种中药牙膏 |
| CN1723011A (zh) * | 2002-06-25 | 2006-01-18 | Wm·雷格利Jr·公司 | 含有厚朴提取物的口气清新和口腔清洁产品 |
| US20060140885A1 (en) | 2004-12-29 | 2006-06-29 | Abdul Gaffar | Method of reducing oral tissue inflammation using magnolia extract |
| WO2008098056A2 (en) * | 2007-02-06 | 2008-08-14 | Epix Pharmaceuticals, Inc. | High relaxivity chelates |
-
2010
- 2010-02-25 ES ES10705965.1T patent/ES2507615T3/es active Active
- 2010-02-25 CN CN201080064851.2A patent/CN102884035B/zh not_active Expired - Fee Related
- 2010-02-25 WO PCT/US2010/025378 patent/WO2011106003A1/en not_active Ceased
- 2010-02-25 US US13/577,627 patent/US8519197B2/en active Active
- 2010-02-25 EP EP10705965.1A patent/EP2539310B1/en active Active
- 2010-02-25 MY MYPI2012003487A patent/MY162466A/en unknown
- 2010-02-25 RU RU2012140748/04A patent/RU2510938C1/ru not_active IP Right Cessation
- 2010-02-25 DK DK10705965.1T patent/DK2539310T3/da active
- 2010-02-25 PH PH1/2012/501619A patent/PH12012501619A1/en unknown
- 2010-02-25 AU AU2010346597A patent/AU2010346597B2/en not_active Ceased
- 2010-02-25 SG SG2012056404A patent/SG183120A1/en unknown
- 2010-02-25 JP JP2012554971A patent/JP2013520495A/ja active Pending
- 2010-02-25 MX MX2012009817A patent/MX2012009817A/es active IP Right Grant
- 2010-02-25 PL PL10705965T patent/PL2539310T3/pl unknown
- 2010-02-25 BR BR112012020603A patent/BR112012020603A2/pt active Search and Examination
- 2010-02-25 CA CA2789140A patent/CA2789140C/en not_active Expired - Fee Related
-
2011
- 2011-02-24 TW TW100106113A patent/TWI438185B/zh not_active IP Right Cessation
- 2011-02-24 AR ARP110100579A patent/AR080656A1/es unknown
-
2012
- 2012-08-10 ZA ZA2012/06020A patent/ZA201206020B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2507615T3 (es) | 2014-10-15 |
| MY162466A (en) | 2017-06-15 |
| CN102884035A (zh) | 2013-01-16 |
| RU2012140748A (ru) | 2014-03-27 |
| AR080656A1 (es) | 2012-04-25 |
| TWI438185B (zh) | 2014-05-21 |
| CA2789140C (en) | 2015-01-27 |
| TW201141823A (en) | 2011-12-01 |
| US20120302647A1 (en) | 2012-11-29 |
| DK2539310T3 (da) | 2014-10-20 |
| CA2789140A1 (en) | 2011-09-01 |
| US8519197B2 (en) | 2013-08-27 |
| AU2010346597B2 (en) | 2013-09-19 |
| SG183120A1 (en) | 2012-09-27 |
| BR112012020603A2 (pt) | 2017-07-11 |
| CN102884035B (zh) | 2016-01-20 |
| HK1180297A1 (en) | 2013-10-18 |
| AU2010346597A1 (en) | 2012-08-23 |
| JP2013520495A (ja) | 2013-06-06 |
| EP2539310B1 (en) | 2014-07-16 |
| PL2539310T3 (pl) | 2015-01-30 |
| WO2011106003A1 (en) | 2011-09-01 |
| RU2510938C1 (ru) | 2014-04-10 |
| ZA201206020B (en) | 2014-01-29 |
| EP2539310A1 (en) | 2013-01-02 |
| PH12012501619A1 (en) | 2014-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012009817A (es) | Sintesis de magnolol y sus compuestos analogos. | |
| US9174956B2 (en) | Process for preparation of 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives and intermediates useful thereof | |
| DD300432A5 (de) | Heterozyklische diaryletherverbindungen | |
| DD229116A5 (de) | Verfahren zur herstellung von phenylverbindungen | |
| IE58958B1 (en) | Leukotriene antagonists | |
| JP2015500875A (ja) | マグノロール類似体を製造するための方法 | |
| JP2015007054A (ja) | マグノロールおよびその類似体化合物の合成 | |
| ES2396524A1 (es) | Intermedios versátiles y funcionalizados en la síntesis de vitamina D y nuevos derivados de vitamina D | |
| EP2522648B1 (en) | Process for producing difluorocyclopropane compound | |
| HK1180297B (en) | Synthesis of magnolol and its analogue compounds | |
| US3097138A (en) | Antiviral biphenylyl glyoxal process and dosage formulations | |
| JPS6296438A (ja) | ４―ヒドロキシ―２―シクロペンテノン類及び薬剤組成物 | |
| JP7220940B2 (ja) | レゾルビンｅ２の安定等価体 | |
| JPS6345232A (ja) | 治療特性を有する新規８−（低級アルキル） ビシクロ〔４．２．０〕オクタン誘導体 | |
| JP3619265B2 (ja) | アスコルビン酸−イノシトール結合体またはその塩、ならびにその製造方法 | |
| Grieco et al. | Synthesis and biological evaluation of the methyl esters of (+)-12-fluoro-13, 14-dihydroprostaglandin F2. alpha. and (+)-15-epi-12-fluoro-13, 14-dihydroprostaglandin F2. alpha. | |
| JPS6144836A (ja) | 置換スチレン誘導体 | |
| JPS6059236B2 (ja) | γ−ピロン誘導体、その製造方法およびそれらの化合物からなる農業用薬剤 | |
| ES8206529A1 (es) | Un procedimiento para la preparacion de derivados de acido 6-amino-penicilanico | |
| KR20150036742A (ko) | 치료 화합물 | |
| BELLUS et al. | Moniliformin and Related Cyclobutenediones | |
| EP0327306A2 (en) | Leukotriene B4 antagonists | |
| SE445553B (sv) | /4h/-1,3-bensodioxan-2-karboxylsyraderivat | |
| JPS60149523A (ja) | 消炎，鎮痛剤 | |
| KR19980065188A (ko) | 무스콘의 신규합성중간체 및 그의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |